Trial Profile
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CASCADE
- Sponsors AstraZeneca AB
- 24 May 2023 Results of post hoc analysis assessing Effect of Tezepelumab on Airway Hyperresponsiveness by Baseline Blood Eosinophil Count in Patients With Severe, Uncontrolled Asthma presented at the 119th International Conference of the American Thoracic Society
- 19 May 2021 Results will be available in early 2021, according to the trial design presented at the 117th International Conference of the American Thoracic Society.
- 19 May 2021 Trial design presented at the 117th International Conference of the American Thoracic Society.